spontan
tumour
regress
follow
bacteri
fungal
viral
protozo
infect
intratumor
infect
may
reactiv
defens
function
caus
tumour
regress
phenomena
inspir
develop
numer
rudimentari
cancer
immunotherapi
start
nonspecif
immunostimulatori
approach
first
use
william
coley
lead
concept
therapeut
vaccin
cancer
recent
identif
character
gene
code
tumour
antigen
ag
enabl
design
antigenspecif
cancer
vaccin
base
plasmid
dna
recombin
viral
vector
gene
therapi
use
manipul
immun
system
help
bodi
natur
defenc
recognis
target
cancer
cell
last
year
estim
europ
almost
cancer
case
diagnos
exclud
non
melanoma
skin
cancer
death
cancer
year
standard
therapeut
procedur
current
practic
includ
surgeri
radiat
chemotherapi
greatli
impact
spread
recurr
progress
malign
reduc
abil
immun
system
provok
spontan
regress
newer
strategi
need
improv
upon
current
treatment
success
rate
histor
wolff
colleagu
first
demonstr
longterm
gene
express
mous
skelet
muscl
could
achiev
direct
intramuscular
inject
plasmid
dna
earli
studi
demonstr
feasibl
direct
intramuscular
gene
transfer
dna
vaccin
purpos
propel
first
vaccin
studi
util
plasmid
dna
protect
scenario
involv
influenza
cellular
humor
immun
respons
demonstr
inject
nake
plasmid
dna
vaccin
dermi
muscl
tissu
mice
respons
induc
protect
preclin
model
infecti
diseas
malign
review
see
donnelli
et
al
dna
vaccin
prime
exampl
modern
genet
vaccin
use
nake
plasmid
dna
vaccin
elicit
immun
system
diseas
provid
varieti
practic
benefit
largescal
vaccin
product
easili
manag
form
vaccin
includ
recombin
protein
whole
tumor
cell
effect
screen
antigen
rapidli
design
specif
type
express
construct
made
studi
dna
vaccin
valuabl
field
immunotherapi
cancer
new
technolog
includ
geneexpress
profil
increas
list
candid
tumor
antigen
investig
focus
target
either
tumourspecif
includ
idiotyp
antigen
bcell
tumour
tumourassoci
antigen
also
express
normal
cell
origin
includ
socal
cancertesti
antigen
exampl
intens
investig
antigen
melanoma
http
wwwcancergovcancertopicstypesmelanoma
prostat
cancer
http
wwwcancergovcancertopicstypesprost
epitheli
cancer
http
wwwcancergovcancertopicstypesskin
dna
vaccin
offer
opportun
incorpor
addit
gene
encod
molecul
aim
overcom
weak
immunogen
tumor
antigen
patient
toler
immun
repertoir
paper
briefli
summar
find
key
technolog
contribut
rapid
progress
dna
vaccin
mode
action
design
optim
dna
vaccin
well
state
art
encourag
clinic
studi
use
tumor
antigen
scientist
identifi
larg
number
cancerassoci
antigen
mani
use
perform
cancer
treatment
vaccin
basic
research
clinic
trial
list
candid
tumor
antigen
grow
daili
larg
expand
genet
technolog
includ
human
genom
sequenc
geneexpress
profil
tumor
antigen
classifi
two
broad
categori
tumorspecif
share
antigen
tumorspecif
uniqu
antigen
share
antigen
tumorassoci
antigen
taa
express
one
type
tumor
cell
number
taa
also
express
normal
tissu
albeit
differ
amount
report
offici
nation
cancer
institut
websit
nci
http
wwwcancergov
repres
exampl
share
antigen
cancertesti
antigen
human
epiderm
growth
factor
receptor
neu
protein
review
carcinoembryon
antigen
cea
uniqu
tumor
antigen
result
mutat
induc
physic
chemic
carcinogen
therefor
express
individu
tumor
tumorspecif
uniqu
antigen
encompass
melanocytemelanoma
differenti
antigen
tyrosinas
prostatespecif
antigen
psa
review
idiotyp
id
antibodi
optim
design
cancer
vaccin
combin
best
tumor
antigen
effect
immunotherapi
agent
deliveri
strategi
achiev
posit
clinic
result
import
dilemma
vaccin
overexpress
tumorassoci
antigen
induc
effect
immun
chosen
target
without
lead
damag
autoimmun
precis
offer
dna
vaccin
induc
focus
immun
select
antigen
becom
power
target
select
care
avoid
autoimmun
recent
nci
pilot
priorit
studi
produc
wellvet
priorityrank
list
cancer
antigen
antigen
priorit
involv
develop
list
ideal
cancer
antigen
criteriacharacterist
assign
rel
weight
criteria
use
pairwis
comparison
result
criteria
weight
follow
therapeut
function
b
immunogen
c
role
antigen
oncogen
specif
e
express
level
percent
antigenposit
cell
f
stem
cell
express
g
number
patient
antigenposit
cancer
h
number
antigen
epitop
cellular
locat
antigen
express
effort
priorit
cancer
antigen
repres
logic
next
step
attempt
focu
translat
effort
cancer
vaccin
regimen
highest
potenti
success
biolog
issu
limit
efficaci
cancer
vaccin
low
immunogen
cancer
antigen
strategi
enhanc
antigen
immunogen
discuss
later
section
dna
vaccin
simpl
vehicl
vivo
transfect
antigen
product
dna
vaccin
compos
plasmid
dna
encod
antigen
interest
control
mammalian
promot
ie
cmvinta
cmv
immediateearli
promot
adjac
intron
sequenc
easili
produc
bacteria
optim
gene
sequenc
interest
deliv
skin
intraderm
subcutaneum
muscl
one
sever
deliveri
method
use
host
cellular
machineri
plasmid
enter
nucleu
transfect
local
cell
myocyt
keratinocyt
includ
resid
antigen
present
cell
apc
gene
express
plasmid
follow
gener
foreign
antigen
although
elucid
immunolog
compon
involv
follow
dna
immun
entir
achiev
mode
action
plasmid
dna
vaccin
appear
twofold
dna
plasmid
deriv
bacteria
stimul
innat
immun
system
interact
tolllik
receptor
receptor
found
apc
although
differenti
express
mice
primat
immun
cell
make
complex
role
adjuv
primat
nonspecif
immun
respons
augment
antigenspecif
immun
respons
direct
indirect
present
antigen
apc
involv
two
overarch
model
propos
antigen
encod
plasmid
produc
host
cell
either
profession
apc
lead
direct
prime
immun
respons
nonprofession
cell
antigen
transfer
apc
lead
crossprim
seri
studi
intend
determin
vaccin
could
work
investig
sourc
ag
present
immunolog
properti
dna
role
cytokin
elicit
immun
respons
earli
studi
show
dna
deliveri
method
affect
cell
type
transfect
gene
gun
bombard
epidermi
plasmid
coat
onto
gold
microbead
tend
directli
transfect
epiderm
keratinocyt
also
langerhan
cell
shown
migrat
rapidli
region
lymph
node
case
profession
apc
transfect
directli
behav
sourc
ag
present
altern
intramuscular
inject
plasmid
predominantli
led
transfect
myocyt
myocyt
lack
express
major
histocompat
complex
class
mhc
ii
costimulatori
molecul
thu
would
expect
prime
lymphocyt
directli
instead
immun
prime
like
occur
dendrit
cell
dc
presum
migrat
site
dna
inocul
respons
inflammatori
chemotact
signal
follow
vaccin
dc
thought
present
antigen
crosspresent
extracellular
antigen
follow
direct
transfect
plasmid
dna
thu
term
induct
immun
influenc
site
procedur
use
inject
muscl
skin
cell
clearli
abl
act
antigen
depot
unabl
prime
immun
respons
like
crosspresent
site
apc
major
rout
prime
also
evid
direct
transfect
apc
especi
deliveri
skin
site
gene
gun
hostsynthes
antigen
process
present
apc
context
mhc
mhc
ii
antigenload
apc
travel
drain
lymph
node
present
peptid
antigen
cell
therebi
elicit
humor
cellular
immun
respons
although
plasmid
dna
vaccin
vector
induc
antibodi
cell
helper
respons
particularli
suit
induc
cell
respons
express
antigen
intracellularli
introduc
directli
mhc
antigen
process
present
pathway
whatev
process
convey
antigen
apc
seem
highli
effici
sinc
dna
vaccin
produc
low
level
antigen
induc
arm
immun
respons
one
lesson
learn
last
year
develop
plasmid
dna
cancer
vaccin
rais
key
issu
need
break
immunolog
toler
gradual
loss
mhc
antigen
tumour
cell
regulatori
cell
could
neg
influenc
induct
antitumour
respons
system
defect
dendrit
cell
secret
immunosuppress
cytokin
resist
apoptosi
discuss
elsewher
use
dna
vector
repres
import
platform
clinic
applic
largescal
vaccin
product
easili
manag
form
vaccin
includ
recombin
protein
whole
tumor
cell
viral
vector
although
viral
mediat
gene
transfer
genet
modifi
lentivirus
adenovirus
adenoassoci
virus
retrovirus
advantag
high
transfect
effici
stabil
largest
hurdl
use
viral
vector
overcom
immunogen
viral
packag
protein
furthermor
viral
method
disadvantag
high
expens
toxic
side
effect
limit
transgen
size
potenti
insert
mutagenesi
one
hand
nonvir
vector
highli
flexibl
capabl
encod
number
immunolog
compon
associ
lower
cytotox
rel
stabl
potenti
costeffect
manufactur
storag
tabl
safeti
term
advers
reaction
inject
demonstr
anim
model
well
human
clinic
trial
first
clinic
trail
initi
monitor
safeti
efficaci
dna
vaccin
infect
demonstr
dna
plasmid
vaccin
safe
capabl
induc
detect
immun
cellular
antibodi
respons
simpl
plasmid
backbon
coupl
technolog
gene
manipul
allow
incorpor
gene
express
cell
transfect
vivo
although
transfect
process
ineffici
vari
target
tissu
mean
deliveri
suffici
dna
gener
taken
prime
immun
respons
dna
vaccin
free
problem
associ
produc
recombin
protein
vaccin
also
safer
live
attenu
caus
pathogen
infect
vivo
addit
studi
dna
vaccin
shown
even
multipl
immun
antidna
antibodi
produc
abil
introduc
antigen
host
immun
system
thu
enabl
elicit
strong
type
cell
cytotox
cell
uniqu
featur
dna
vaccin
make
distinct
convent
protein
peptid
vaccin
featur
readili
induc
humor
well
cellular
immun
respons
plasmidbas
gene
transfer
also
deliv
oligonucleotid
alter
gene
splice
gene
express
exampl
sirna
earli
develop
dna
vaccin
becam
clear
maxim
express
encod
ag
critic
induct
potent
immun
respons
strong
viral
promot
cmvinta
gener
favour
regul
endogen
eukaryot
promot
furthermor
nuclear
target
sequenc
nt
could
introduc
increas
effici
nuclear
plasmid
uptak
cytoplasm
intramuscular
inject
util
codonoptim
sequenc
instead
wildtyp
code
sequenc
gener
potent
method
improv
vaccin
optim
code
sequenc
determin
back
amino
acid
sequenc
antigen
algorithm
take
account
abund
specif
trna
cytosol
human
cell
predict
structur
mrna
thereaft
select
gene
sequenc
construct
vitro
use
synthet
oligonucleotid
advers
rare
codon
avoid
secondari
structur
mrna
minim
therebi
synthet
gene
optim
express
consequ
induct
immun
respons
flexibl
plasmid
design
coupl
technolog
gene
manipul
allow
also
gene
optim
inde
variabl
region
heavi
vh
light
chain
vl
tumor
immunoglobulin
specif
bcell
malign
readili
clone
combin
singlechain
variabl
fragment
scfv
format
encod
singl
polypeptid
consist
vh
vl
gene
link
togeth
frame
short
acid
linker
alreadi
discuss
backbon
bacteri
dna
includ
cytosinephosphateguanin
cpg
unmethyl
region
sequenc
motif
stimul
innat
immun
creat
inflammatori
milieu
trigger
adapt
immun
respons
role
cpg
motif
adjuv
immun
respons
dna
vaccin
well
document
mice
preclin
studi
show
addit
cpg
motif
plasmid
result
induct
proinflammatori
cytokin
exampl
ifni
cpg
recogn
receptor
found
apc
help
cytotox
tlymphocyt
ctl
differenti
prime
coadministr
gene
encod
ligand
tolllik
receptor
tlr
signal
molecul
shown
improv
immunogen
dna
vaccin
engin
dna
vaccin
design
maxim
epitopespecif
immun
allow
epitop
enhanc
sequenc
modif
recent
molecular
understand
immun
respons
lead
new
strategi
induc
effect
immun
respons
selftoler
might
lead
delet
cell
specif
effect
epitop
leav
lowavid
cell
therefor
sequenc
optim
antigen
epitop
process
term
epitop
enhanc
expect
make
sequenc
mani
epitop
cancer
immunogen
epitop
sequenc
modifi
increas
affin
epitop
peptid
mhc
molecul
knowledg
sequenc
motif
peptid
bind
key
improv
primari
andor
secondari
anchor
residu
provid
much
specif
bind
mhc
molecul
strategi
greatli
increas
potenc
vaccin
convert
subdomin
epitop
domin
one
make
competit
avail
mhc
molecul
therebi
increas
level
specif
complex
antigen
present
cell
surfac
epitop
enhanc
use
increas
affin
mhc
class
class
ii
molecul
review
enhanc
immunogen
dna
vaccin
encod
immunostimulatori
rna
doublestrand
rna
replicon
rna
also
gener
engin
vaccin
design
manipul
antigen
present
process
pathway
one
import
aspect
easili
handl
dna
vaccin
technolog
antibodi
respons
goal
clearli
desir
direct
antigen
express
endoplasm
reticulum
er
fold
secret
occur
appropri
leader
signal
sequenc
achiev
review
induct
ctl
addit
gene
encod
molecul
ubiquitin
aim
enhanc
degrad
peptid
product
proteasom
effect
review
similarli
target
express
differ
subcellular
pathway
endosom
lysosom
amplifi
cell
respons
thu
dna
vaccin
design
induc
appropri
effector
pathway
includ
antibodi
cellsurfac
antigen
ctl
respons
intracellular
antigen
express
mhc
class
iassoci
peptid
sinc
tumor
antigen
often
weakli
immunogen
immun
repertoir
patient
may
toler
central
question
whether
dna
vaccin
activ
maintain
high
level
immun
requir
suppress
cancer
cell
growth
pivot
posit
helper
th
cell
help
b
cell
produc
antibodi
control
induct
mainten
cell
led
investig
focu
import
respons
dna
vaccin
select
gene
encod
microbi
protein
fuse
tumor
antigen
sequenc
possibl
activ
th
cell
dramat
amplifi
immun
tumor
cell
discuss
follow
section
dna
vaccin
offer
opportun
activ
th
cell
transform
weak
ineffect
immun
power
antitumor
attack
even
though
specif
antibodi
ctl
respons
could
induc
clinic
trial
nake
dna
vaccin
intramuscular
intraderm
rout
high
dose
dna
necessari
elicit
detect
immun
respons
larg
quantiti
mg
requir
induc
modest
immunogen
modifi
microenviron
vaccin
site
coadministr
genet
dna
plasmid
code
immunostimulatori
molecul
protein
chemic
adjuv
improv
low
immunogen
dna
vaccin
progress
made
develop
improv
techniqu
encapsul
plasmid
dna
liposom
polym
microparticl
although
formul
shown
elicit
immun
respons
superior
elicit
simpl
intramuscular
plasmid
dna
still
disappoint
human
clinic
trial
consid
eas
design
construct
plasmid
dna
use
target
particular
neoplasm
biolog
adjuv
tailor
encod
within
dna
vector
well
vast
array
molecul
abl
modul
immun
respons
deliv
tabl
includ
chemokin
attract
apc
activ
cytokin
costimulatori
molecul
apctarget
antibodi
molecul
manipul
antigen
present
andor
process
one
common
cytokin
employ
plasmid
dna
vaccin
factor
gmcsf
molecul
abl
enhanc
immun
respons
induc
prolifer
matur
migrat
dc
well
expans
differenti
b
lymphocyt
addit
codeliveri
dna
vaccin
allow
fusion
gene
encod
activ
molecul
antigenencod
sequenc
advantag
fusion
gene
creat
singl
vaccin
capabl
multipl
function
biragyn
colleagu
show
effici
dna
vaccin
vivo
could
greatli
increas
encod
fusion
protein
consist
scfv
fuse
proinflammatori
chemokin
moieti
facilit
target
apc
chemokin
receptormedi
bind
uptak
process
scfv
antigen
subsequ
present
cell
two
independ
model
vaccin
dna
construct
encod
fusion
protein
consist
scfv
fuse
monocyt
chemotact
protein
interferon
induc
protein
gener
superior
protect
larg
tumor
challeng
time
minimum
lethal
dose
compar
best
avail
protein
vaccin
addit
strategi
activ
effect
immun
poorli
immunogen
tumor
antigen
employ
dna
fusion
gene
vaccin
activ
cell
help
antitumor
respons
th
cell
pivot
cell
immun
respons
abl
induc
high
level
immun
mainten
respons
extens
studi
stevenson
cowork
requir
foreign
sequenc
induc
th
bcell
respons
help
ctl
respons
known
mani
year
sinc
th
cell
control
respons
vaccin
quit
obviou
selfantigen
contain
epitop
like
recogn
avail
th
cell
incap
induc
immun
strategi
activ
th
cell
induc
antitumor
immun
engag
repertoir
nontoler
antigen
use
xenogen
antigen
break
toler
like
due
presenc
foreign
sequenc
xenogen
antigen
abl
activ
th
cell
focus
antimicrobi
repertoir
principl
appli
realiz
dna
fusion
gene
vaccin
encod
tumor
antigen
link
antigen
deriv
tetanu
toxin
fusion
fragment
c
frc
tetanu
toxin
amplifi
immun
respons
rang
tumor
antigen
lead
suppress
tumor
growth
clinic
trial
use
approach
break
selftoler
therapeut
purpos
patient
lymphoma
prostat
carcinoma
discuss
elsewher
increasingli
appar
immunogen
dna
vaccin
greatli
depend
upon
deliveri
method
use
immun
melanoma
mous
model
dna
vaccin
administ
togeth
intratumor
deliveri
antiangiogen
plasmid
encod
angiostatin
endostatin
combin
melanoma
vaccin
result
tumorfre
surviv
day
challeng
modest
proport
patient
malign
diseas
intratumor
inject
dna
led
regress
tumor
distant
site
recent
studi
confirm
physic
method
superior
deliveri
method
administ
dna
variou
chemic
solut
biolist
gene
gun
deliveri
involv
adher
nake
dna
gold
bead
shoot
particl
highpressur
instrument
system
deliv
dna
directli
skin
langerhan
cell
highli
effici
process
gene
gun
immun
shown
induc
greater
cell
respons
well
requir
less
vaccin
achiev
tumor
immun
promis
strategi
electropor
ep
primat
increas
level
also
breadth
respons
overcom
difficulti
translat
effect
dna
vaccin
preclin
rodent
larg
anim
includ
human
subject
electroporationbas
dna
deliveri
technolog
dramat
enhanc
cellular
uptak
dna
vaccin
ep
work
adjuv
enhanc
necessari
danger
signal
becom
detect
immun
system
tissu
damag
caus
applic
ep
caus
inflamm
recruit
dc
macrophag
lymphocyt
inject
site
induc
signific
immun
respons
includ
antibodi
tcell
respons
moreov
toler
without
anesthet
induc
unwant
immun
respons
deliveri
mechan
therefor
use
repeat
administr
newli
develop
intraderm
dna
deliveri
tattoo
technolog
tattoo
devic
cartridg
nine
fine
metal
perfor
needl
oscil
constant
high
frequenc
punctur
skin
lead
dna
transfer
skinassoci
cell
express
report
gene
result
robust
tcell
respons
recent
tattooimmun
appli
phase
studi
assess
toxic
efficaci
induc
tumorspecif
tcell
immun
melanoma
vaccin
schedul
base
combin
primeboost
regimen
use
differ
vector
system
deliv
desir
antigen
ie
heterolog
primeboost
immun
regimen
appear
success
improv
dna
vaccin
platform
actual
primeboost
regimen
shown
promis
elicit
greater
immun
respons
human
compar
dna
vaccin
alon
dnaprimevir
vectorboost
approach
focus
induct
tcell
immun
respons
approach
homolog
boost
immun
carri
equival
antigen
previou
immun
viral
vector
test
booster
vaccin
includ
adenoviru
vaccinia
viru
fowlpox
well
recombin
vesicular
stomat
viru
likewis
dnaprimeproteinboost
approach
employ
recombin
protein
antigen
match
antigen
use
dna
prime
immun
strategi
aim
develop
balanc
humor
cellmedi
immun
respons
focu
elicit
high
qualiti
protect
antibodi
respons
heterolog
primeboost
vaccin
regimen
exploit
abil
immun
system
gener
larg
number
secondari
antigenspecif
cell
follow
prime
immun
proport
antigenspecif
cell
popul
transform
antigenspecif
memori
cell
abil
expand
rapidli
upon
encount
antigen
secondtim
round
sinc
prime
boost
vector
differ
strategi
allow
greater
expans
diseas
antigenspecif
cell
popul
date
heterolog
primeboost
regimen
among
potent
strategi
induc
cellular
immun
respons
compar
homolog
primeboost
approach
dna
vaccin
boost
primari
respons
heterolog
vector
result
higher
cell
respons
one
end
combin
dna
vaccin
ep
homolog
primeboost
approach
could
gener
antibodi
respons
compar
induc
protein
complet
freund
adjuv
also
amplifi
ctl
respons
ep
may
provid
primeboost
combin
equival
observ
use
viral
vector
undergo
test
clinic
use
dna
vaccin
patient
prostat
cancer
repeat
ep
accept
patient
without
need
gener
local
anaesthesia
appar
longterm
ill
effect
immun
suppress
featur
tumor
microenviron
barrier
tumor
immun
therapi
microenviron
tumor
establish
activ
myeloid
lymphoid
regulatori
cell
well
product
immunesuppress
factor
malign
cell
mani
tumorinfiltr
macrophag
refer
myeloidderiv
suppressor
cell
mdsc
immunesuppress
phenotyp
macrophag
abund
mani
tumor
aris
human
mice
exert
power
antiinflammatori
effect
addit
mdsc
regulatori
cell
treg
also
heavili
infiltr
mani
tumor
cell
character
express
transcript
factor
well
play
key
role
regul
adapt
immun
treg
suppress
immun
respons
secret
suppress
cytokin
like
il
treg
potenti
barrier
develop
product
immun
therapi
cancer
repres
attract
target
enhanc
antitumor
immun
cancer
immunotherapi
design
specif
target
cancer
type
use
compon
immun
system
therefor
dna
vaccin
also
face
mani
obstacl
includ
break
peripher
cell
toler
tumor
selfantigen
elicit
appropri
immun
reaction
well
overcom
tumorderiv
immunosuppress
network
evas
tactic
evas
mechan
adopt
malign
cell
prevent
immun
cell
function
numer
lead
clonal
expans
nonimmunogen
tumor
cell
loss
tumor
antigen
apoptosi
prevent
tumour
cell
downregul
express
mhc
target
antigen
often
secret
immunosuppress
molecul
defend
attack
tumour
creat
tolerogen
environ
spread
drain
lymph
node
enhanc
regulatori
tcell
activ
hurdl
success
revers
toler
induct
effect
immun
becom
clear
vaccin
must
incorpor
element
overcom
furthermor
cancer
cell
secret
solubl
factor
tumor
microenviro
exampl
vegf
affect
matur
differenti
activ
apc
dc
interf
immun
cell
matur
effector
properti
tumour
microenviron
may
drive
tumour
growth
even
select
support
subset
tumour
cell
cancer
stem
cell
csc
dna
vaccin
platform
capabl
suppress
progress
alreadi
establish
tumor
target
secret
solubl
factor
tumor
microenviron
revers
immunolog
attenu
mechan
improv
dna
vaccin
potenc
concept
combin
cancer
vaccin
angiogenesi
inhibit
appeal
due
favor
safeti
profil
approach
well
possibl
biolog
synergi
dna
vaccin
mice
vegf
receptor
abrog
tumor
vasculatur
protect
dna
vaccin
anim
tumor
challeng
prophylact
approach
express
plateletderiv
growth
factor
receptor
pdgfr
stromal
cell
directli
correl
advanc
stage
diseas
human
colorect
cancer
dna
vaccin
suppress
growth
dissemin
human
colorect
cancer
cell
inject
mice
vivo
coadministr
plasmid
encod
chemokin
macrophag
inflammatori
dcspecif
growth
factor
fmslike
tyrosin
kinas
ligand
plasmid
dna
augment
immunogen
vaccin
mobil
activ
larg
number
dc
site
inocul
consist
concept
effect
cancer
therapi
multimod
combin
treg
deplet
activ
cancer
immunotherapeut
intervent
attract
prospect
support
abund
data
mice
preliminari
human
trial
lastli
addit
strategi
aim
alter
regulatori
cell
function
cancer
immunotherapi
includ
block
treg
traffick
differenti
andor
function
reduc
effector
cell
suscept
suppress
alreadi
proven
success
preliminari
studi
dna
vaccin
attract
effect
approach
activ
therapeut
vaccin
bcell
malign
given
eas
product
compar
id
protein
vaccin
patientspecif
dna
vaccin
therapi
b
cell
lymphoma
multipl
myeloma
base
scfv
encod
chimer
immunoglobulin
molecul
consist
vh
vl
gene
deriv
patient
tumor
shown
effect
anim
model
first
phase
iii
trial
idiotyp
vaccin
follicular
bcell
lymphoma
use
genet
approach
conduct
hawkin
colleagu
vaccin
encod
individu
dna
idiotyp
scfv
fuse
ttfrc
deliv
nake
dna
im
inject
patient
follicular
lymphoma
clinic
remiss
follow
chemotherapi
plasmid
dna
abl
develop
cellular
orand
humor
antiidiotyp
immun
respons
patient
period
sever
month
second
studi
vaccin
therapi
bcell
lymphoma
patient
tumor
scfv
link
mous
immunoglobulin
heavi
lightchain
constant
region
chain
respect
phase
iii
trial
patient
remiss
chemotherapi
receiv
two
seri
im
dna
vaccin
end
second
vaccin
patient
exhibit
humor
andor
tcell
antiid
respons
yet
crossreact
id
protein
patient
tumor
subsequ
third
seri
vaccin
carri
use
human
gmcsf
dna
mix
id
dna
humor
tcell
respons
boost
case
import
insight
provid
preclin
studi
depart
oncolog
univers
hospit
uppsala
recruit
particip
phase
iii
trial
intraderm
ep
derma
vax
use
deliveri
system
studi
assess
feasibl
safeti
vaccin
increas
dose
xenogen
dna
code
rhesu
prostat
specif
antigen
rhpsa
protein
homolog
human
psa
administ
patient
relaps
prostat
cancer
phase
iii
dose
escal
dna
vaccin
trial
plasmid
dna
carri
prostatespecif
membran
antigen
psma
fuse
domain
fragment
c
tetanu
toxin
deliv
either
im
im
follow
ep
perform
patient
recurr
prostat
cancer
epitop
use
studi
short
stretch
amino
acid
tumorderiv
epitop
belong
psma
preliminari
analysi
tcell
reactiv
prostatespecif
membran
antigen
target
peptid
indic
signific
respons
patient
tcell
respons
data
valid
ep
potent
method
stimul
humor
respons
induc
dna
vaccin
human
result
phase
iii
trial
conduct
dna
vaccin
encod
human
prostat
acid
phosphatas
pap
coadminist
intraderm
gmcsf
prostat
cancer
patient
stage
associ
increas
psa
doubl
time
psadt
month
pretreat
versu
month
year
posttreat
longer
psadt
associ
extrem
low
risk
death
prostat
cancer
besid
patient
develop
papspecif
ifn
gammasecret
tcell
immedi
treatment
cours
patient
develop
papspecif
andor
tcell
prolifer
confirm
preclin
studi
todorova
colleagu
enhanc
dna
vaccin
efficaci
heterolog
primeboost
regimen
phase
iii
studi
prostat
cancer
patient
primeboost
altern
inject
recombin
adenovir
vector
express
psma
plasmid
dna
encod
psma
alongsid
receiv
gmcsf
protein
adjuv
observ
period
first
vaccin
inject
particip
develop
antipsma
antibodi
dna
vaccin
platform
promis
therapeut
approach
also
treatment
malign
melanoma
demonstr
alreadi
complet
ongo
clinic
trial
stage
iv
melanoma
patient
phase
iii
pilot
studi
intranod
deliveri
synchrotop
plasmid
dna
vaccin
induc
humor
ctl
respons
cell
express
tumor
two
melanomaassoci
antigen
synchrotop
plasmid
bival
dna
vaccin
encod
epitop
melana
tyrosinas
potenti
antineoplast
activ
approach
use
improv
trial
conduct
synchrovax
sem
plasmid
dna
vaccin
contain
plasmid
psem
encod
peptid
epitop
sequenc
melana
melana
tyrosinas
tyrosinas
result
antigenspecif
immun
even
though
induc
regress
establish
diseas
dna
plasmid
encod
nonmut
melanomamelanocyt
antigen
alon
administ
patient
metastat
melanoma
rosenberg
et
al
show
neither
intramuscular
intraderm
inject
capabl
rais
cellular
immun
reactiv
signific
incid
antitumor
effect
increas
result
obtain
phase
ii
studi
cytokin
adjuv
use
combin
vaccin
protocol
clinicaltrialsgov
identifi
phase
ii
trial
human
gmcsf
plasmid
dna
conjunct
multipeptid
vaccin
encod
tyrosinas
peptids
current
vaccin
strategi
base
induct
neutral
antibodi
major
minor
capsid
protein
human
papillomaviru
gardasil
effect
subset
hpv
genotyp
therapeut
intervent
earlystag
latestag
cervic
cancer
hpvrelat
diseas
uneffect
dna
plasmid
platform
could
repres
ideal
vaccin
hpv
infect
sinc
could
gener
humor
immun
respons
prevent
new
infect
well
cellmedi
immun
elimin
establish
infect
recent
phase
iii
clinic
trial
patient
highgrad
squamou
intraepitheli
lesion
associ
provid
dna
plasmid
express
mutat
nonfunct
incap
bind
retinoblastoma
protein
transform
activ
link
signal
sequenc
also
attach
hybrid
antigen
result
secret
link
antigen
hpv
antigen
well
antigen
essenti
transform
coexpress
hpvassoci
lesion
henc
repres
ideal
target
develop
hpv
therapeut
vaccin
preclin
studi
mice
success
dnabas
immun
primeboost
approach
coadministr
plasmid
dna
encod
murin
alpha
fetoprotein
afp
murin
gmcsf
follow
boost
afpexpress
nonrepl
adenovir
vector
lead
tumor
protect
immun
earli
studi
appli
phase
iii
clinic
trial
patient
hlaa
stage
hepatocellular
carcinoma
vaccin
therapi
compris
afp
sargramostim
gmcsf
plasmid
dna
follow
afp
adenovir
vector
boost
determin
doselimit
toxic
maximum
toler
dose
adjuv
vaccin
clinicaltrialsgov
identifi
sinc
oncogen
protein
tumor
antigen
patient
breast
ovarian
cancer
sever
vaccin
strategi
develop
evalu
safeti
immunogen
phase
ii
clinic
trial
clinicaltrialsgov
patient
whose
tumor
overexpress
antigen
detect
antibodi
tcell
immun
direct
likewis
preclin
studi
suggest
protein
particularli
intracellular
domain
icd
tumor
reject
antigen
salazar
colleagu
studi
immun
respons
patient
overexpressess
epitop
undergon
vaccin
therapi
heterolog
primeboost
regimen
clinicaltrialsgov
identifi
vaccin
plasmid
encod
icd
patient
advanc
stage
overexpress
breast
ovarian
cancer
patient
receiv
icd
protein
treatment
intraderm
month
postvaccin
vaccin
inject
site
biopsi
examin
infiltr
tcell
antigenpres
cell
popul
blood
sampl
examin
presenc
memori
marker
demonstr
develop
icd
memori
immun
plasmid
dna
new
gener
biotechnolog
product
begin
enter
marketplac
progress
applic
dna
vaccin
immun
protocol
evid
increas
number
vaccin
evalu
clinic
trial
recent
approv
sever
dna
vaccin
product
veterinari
applic
goal
dna
vaccin
develop
effect
immun
strategi
previous
establish
tumor
toler
tumour
antigen
effort
ongo
optim
dna
vaccin
technolog
platform
strategi
improv
antigen
express
inclus
adjuv
formul
immun
modul
improv
immunogen
use
nextgener
deliveri
method
intens
investig
current
effort
priorit
cancer
antigen
repres
logic
next
step
attempt
focu
translat
effort
promis
cancer
antigen
vaccin
cancer
treatment
prevent
like
vaccin
combin
treatment
modal
becom
appreci
vaccin
approach
may
enhanc
subsequ
respons
radiotherapi
certain
chemotherapi
actual
enhanc
respons
vaccin
accordingli
sever
latestag
clinic
trial
alreadi
evalu
benefit
vaccin
addit
convent
chemotherapi
one
attract
set
patient
complet
remiss
standard
adjuv
treatment
chemotherapi
radiotherapi
etc
combin
vaccin
given
immunolog
recoveri
combin
immunotherapi
convent
chemotherapi
antiangiogen
therapi
approach
could
yield
synergist
addit
therapeut
result
still
much
term
optim
vaccin
design
activ
select
appropri
target
antigen
improv
immun
recruit
deliveri
technolog
nevertheless
next
year
increas
number
dna
vaccin
enter
advanc
phase
human
studi
aim
establish
efficaci
real
clinic
product
therapeut
regimen
compos
optim
vaccin
formul
combin
immunotherapi
agent
deliveri
strategi
could
offer
hope
patient
suffer
incur
cancer
current
standard
therapi
provid
alon
